Objective:To analyze the effects of cellular immunity assisted endostar,interventional embolization on medium and long term survival time in patients with advanced hepatocellular carcinoma. Methods:The patients with advanced hepatocellular carcinoma treated in our hospital from July 2011 to December 2014 were included in the study,and their clinical data were analyzed retrospectively. 30 patients treated with endostar and interventional emboli-zation were screened in the control group,and another 30 patients treated with cellular immune assisted therapy on this basis were included in the observation group. The clinical efficacy,the levels of T lymphocyte and NK cell and liver cancer specific biochemical markers alpha fetoprotein (AFP),the survival time and the incidence rates of complica-tions were compared between the two groups. Results:Among the patients with advanced hepatocellular carcinoma , the total effective rate in the observation group was significantly higher than that in the control group (90. 00% vs 70. 00%). After treatment,the levels of T lymphocytes CD3 +,CD4 +,CD4 +/CD8 +and NK cells in the observation group were significantly increased and higher than those in the control group,and the levels of CD8 +,regulatory T cells (Treg)and AFP were significantly decreased and lower than those in the control group,and there was only sta-tistically significant difference in the levels of CD4 +,CD8 +,CD4 +/CD8 +and AFP in the control group (P＜0. 05), and there was no difference in other indexes levels (P＞0. 05). And the incidence rate of complications in the obser-vation group was significantly lower than that in the control group (20. 00% vs 46. 67%),and the proportion of pa-tients with survival time more than 1 year was significantly higher than that in the control group (53. 33% vs 26. 67%). The disease-free survival time and the total survival time of the observation group were longer than those of the control group (P＜0. 05). Conclusion:Cellular immunity assisted endostar,interventional embolization for ad-vanced liver cancer can achieve the long survival time,and can increase the patient's treatment tolerance and have low incidence rate of complications.%目的:分析细胞免疫辅助恩度、介入栓塞对中晚期肝癌患者中长期生存时间的影响.方法:将2011年7月至2014年12月于我院治疗的中晚期肝癌患者纳入本研究,回顾性分析其临床资料,筛选恩度联合介入栓塞治疗的30例患者纳入对照组,将在此基础上予以细胞免疫辅助治疗的30例患者纳入观察组,对比两组临床疗效、T淋巴细胞及NK细胞水平、肝癌特异性生化指标甲胎蛋白(AFP)水平、生存时间及并发症发生率.结果:两组中晚期肝癌患者中,观察组临床总有效率为90. 00%,显著高于对照组的70. 00%;且经治疗后,观察组T淋巴细胞CD3 +、CD4 +、CD4 +/CD8 +及NK细胞均有显著上升且高于对照组,CD8 +、调节性T细胞(Treg)及AFP水平均显著下降且低于对照组,对照组仅CD4 +、CD8 +、CD4 +/CD8 +及AFP等指标水平变化有统计学差异(P＜0. 05),其他均无统计学差异(P＞0. 05);同时,观察组并发症发生率仅为20. 00%,显著低于对照组的46. 67%,其中生存时间＞1年患者占比53. 33%,显著高于对照组的26. 67%;疾病无进展生存期、总生存期均较对照组长,对比差异有统计学意义(P＜0. 05).结论:细胞免疫辅助恩度、介入栓塞治疗中晚期肝癌能获取更长的生存时间,并能增加患者治疗的耐受性,并发症发生率更低.
展开▼
